Key Takeaways:
Agios Pharmaceuticals Inc. secured exclusive global rights to cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia, in a licensing deal with South Korea's Oscotec that carries up to $1 billion in peak U.S. sales potential.
"Cevidoplenib is a next-generation SYK inhibitor uniquely designed to potentially offer improved tolerability and durability compared to first-generation SYK inhibitors," Brian Goff, chief executive officer of Agios, said. "Backed by clinically meaningful Phase 2 data, we believe cevidoplenib has the opportunity to become a best-in-class treatment option for ITP."
Oscotec will receive $25 million upfront and is eligible for up to $140 million in development and regulatory milestones across as many as three indications in the U.S. and Europe, plus commercial milestone payments and tiered royalties ranging from high single-digit to mid-teen percentages on future net sales. Agios will assume full responsibility for all future development and commercialization costs. Oscotec retains an option to reclaim exclusive rights in South Korea after Phase 3 data are released.
The deal expands Agios' rare hematology portfolio beyond its approved therapy mitapivat (PYRUKYND) into ITP, a rare autoimmune blood disorder affecting an estimated 200,000 people globally, including 90,000 adults in the U.S. Of those, roughly 50,000 have chronic disease requiring treatment, and about 24,000 have progressed beyond initial therapies. Current standard-of-care options carry limitations including delayed onset, lack of durable efficacy, and class-specific adverse events such as decreased blood counts and increased infection risk.
Cevidoplenib is a highly selective SYK inhibitor designed to block autoantibody-mediated platelet destruction, the primary driver of ITP. SYK is a signaling enzyme involved in antibody-driven immune cell activation; by targeting SYK-dependent pathways, the drug aims to reduce platelet clearance and restore counts. Its selectivity is intended to improve on first-generation SYK inhibitors' tolerability for long-term use. The FDA has granted cevidoplenib orphan drug designation for ITP.
The Phase 2 trial enrolled 60 adults with platelet counts below 30,000/µL who had relapsed after or were refractory to at least one prior therapy. Patients were randomized 1:2:2 to placebo, 200 mg twice daily, or 400 mg twice daily for 12 weeks. The population was heavily pretreated — 68.3% had received three or more prior lines of therapy, 68.3% had baseline platelet counts below 15,000/µL, and 81.7% had relapsed disease.
The novel primary endpoint — platelet count of at least 30,000/µL with doubling from screening at any visit without rescue medication — did not reach statistical significance. However, durable platelet responses were observed across multiple secondary endpoints that align with primary endpoints used in ITP registrational trials, including at least two consecutive platelet counts of 30,000/µL and 50,000/µL. Cevidoplenib was well tolerated, with the most common treatment-related adverse events being transient liver enzyme elevations and gastrointestinal events. No new safety signals emerged.
Agios expects to advance cevidoplenib into Phase 3 development in the first half of 2028, following completion of additional chemistry, manufacturing, and controls work. The company said its 2026 operating expense guidance remains approximately flat compared with 2025, excluding the $25 million upfront payment.
The licensing deal signals Agios' intent to build a diversified rare hematology franchise beyond its current focus on pyruvate kinase deficiency and thalassemia. For investors, the key catalyst will be the Phase 3 readout, which will determine whether cevidoplenib can capture a meaningful share of the roughly 24,000 later-line ITP patients in the U.S. who lack adequate treatment options.
This article is for informational purposes only and does not constitute investment advice.
